# Axial VC

> Axial VC is a VC fund backing Biotechnology and Health Care. See 22 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 22
- Last investment: May 2025
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/65302041/admin/
- X (Twitter): https://twitter.com/AxialXYZ
- Website: https://axialvc.com/
- Facebook: https://www.facebook.com/profile.php?id=100057684900087

Axial VC is a VC fund focused on Biotechnology and Health Care. Agency for great inventors

## Contacts

5 contacts available for Axial VC. Shizune tracks 1 team members at Axial VC. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/axial-vc?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $4.3M–$17M |
| Pre-Seed | $750k–$6M |
| Series A | $12M–$55M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 16 | 73% |
| Health Care | 7 | 32% |
| Life Science | 7 | 32% |
| Therapeutics | 4 | 18% |
| Medical | 3 | 14% |

27 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 10 | 45% |
| Pre-Seed | 7 | 32% |
| Series A | 4 | 18% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 17 | 77% |
| Switzerland | 1 | 5% |
| United Kingdom | 1 | 5% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Joshua Elkington | Founder and General Partner | 0 | https://shizune.co/investors/profile/joshua-elkington-54d8 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Stately Bio | Stately Bio is the trade-off between measuring cells and keeping them alive. Our patented ML technology measures cell identity, behavior, and maturation—all directly from live-cell, label-free imaging. | $12M | Seed | May 01, 2025 |  |
| Potato | AI research assistant for biology. | $1M | Pre-Seed | Oct 28, 2024 |  |
| Insamo | Insamo offers the discovery of membrane-permeable & orally available cyclic-peptides which lies in its automated process of designing, synthesizing, and testing at an unprecedented scale. | $12M | Seed | Feb 21, 2024 |  |
| omica.ai | Omica turns real-world clinical data into structured training infrastructure for biomedical AI. We partner with hospitals and labs to extract, standardize, and validate multimodal patient data — including notes, pathology, imaging, and genomics. Our pipeline combines automation with clinical oversight to produce longitudinal, de-identified datasetsready for research and model training. Through our platform, Atlas, clients can define cohorts, access structured outputs, and power applications in real-world evidence and predictive modeling. Our data assets are already used by leading AI diagnostics companies and global pharma teams building the next generation of clinical tools. | $1M | Pre-Seed | Feb 16, 2024 |  |
| Aperiam Bio | Aperiam Bio partners with enzyme engineers and distributors to create and share stabilized, solubilized, and catalytically optimized proteins. The company was founded in 2021 and is headquartered in Austin, Texas, United States. | $9M | Seed | Nov 29, 2023 |  |
| Nalu Bio | Nalu Bio is a biotech company developing CBD (and cannabinoids) through chemistry (not plants), for companies who want pure and safe ingredients that are better for the planet. Ranked as the #1 CBD producer on the “google for ingredients.” Like plant-based meats, Nalu Bio will fundamentally disrupt CBD production with chemistry. Nalu Bio uses 700xless land, 70x less water, and 14x less energy to produce its cannabinoids while ensuring best-in-class purity and quality (0% THC, no chemicals, no pesticides) without the high capital investment costs of hemp extraction and biosynthesis. | $12M | Series A | Feb 28, 2023 |  |
| Infinimmune | Infinimmune operates as a biotechnology company. Infinimmune reinvents antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. | $12M | Seed | Dec 06, 2022 |  |
| Meliora Therapeutics | Meliora Therapeutics is a biotech startup that is developing a machine learning-driven platform to identify the true mechanisms of action of oncology medications. | $11M | Seed | Sep 29, 2022 |  |
| Meliora Therapeutics | Meliora Therapeutics is a biotech startup that is developing a machine learning-driven platform to identify the true mechanisms of action of oncology medications. | $11M | Seed | Sep 29, 2022 |  |
| Network Bio | Network Bio is a clinical and molecular data library enabling precision medicine approaches for common human diseases. Its platform delivers a centralized repository for clinical and molecular data that allows researchers to identify patterns and correlations that can be used to develop new treatments and diagnostic tools. | $2.5M | Pre-Seed | Sep 01, 2022 |  |

10 of 22 investments shown.

## Co-investors
- [Artis Ventures](https://shizune.co/investors/profile/artis) — VC Fund, 5 deals together
- [Civilization Ventures](https://shizune.co/investors/profile/civilization-ventures) — VC Fund, 5 deals together
- [OMX Ventures](https://shizune.co/investors/profile/omx-ventures) — VC Fund, 5 deals together
- [BrightEdge Fund](https://shizune.co/investors/profile/brightedge-fund) — VC Fund, 3 deals together
- [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners) — VC Fund, 3 deals together
- [Playground Global](https://shizune.co/investors/profile/playground-global) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [SICTIC](https://shizune.co/investors/profile/sictic) — VC Fund
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund

## Featured in investor lists
- [Life Science VC Funds in United States](https://shizune.co/investors/life-science-vc-funds-united-states)
- [Life Science Investors in Switzerland](https://shizune.co/investors/life-science-investors-switzerland)

## FAQ

### What does Axial VC invest in?

Axial VC invests primarily in Biotechnology, Health Care and Life Science startups, most often at Seed and Pre-Seed stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Axial VC's check size?

Axial VC typically joins rounds of $4.3M–$17M at Seed, $750k–$6M at Pre-Seed and $12M–$55M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Axial VC participates in.

### How do I contact Axial VC?

Public channels for Axial VC include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Axial VC?

The team at Axial VC includes Joshua Elkington (Founder and General Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co